The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index; 9 of the 106 sources its claims cite were checked for support.
Abstract
In the past decade, the number of papers dealing with treatment resistance in depression has increased to a considerable degree. It has recently been discussed whether current definitions of treatment resistance are appropriate: issues of misdiagnosis, diagnostic and biological heterogeneity, and suboptimal therapeutic strategies have been raised [1-3]. However, current conceptualizations of treatment resistance focus on the characteristics of the patient (whether neurobiological assets, or attitudes, or psychiatric comorbidity) for the insufficient effectiveness of antidepressant drugs and omit any reference to the potential iatrogenic effects of treatment [4], as if, in the field of infectious disease, treatment resistance were conceptualized independently of the previous use of antibiotics. \nWe will try to outline some historical developments of the concept of treatment resistance in depression and how a different assessment strategy is required to address current clinical challenges.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 4 Not valid · 68 Not checked · 26 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A particular form of resistance occurs when a drug which resulted in clinical response in previous episodes is no longer effective when it is started again after a drug-free period.”
What the sources say
- Supportedcites [26] matched to “Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience” (2018) source
The intro passage of our copy (unnumbered section, p. 1) explicitly lists among antidepressant-related clinical phenomena 'lack of response to a previously effective treatment when it is started again after a drug-free period', and the oppositional-tolerance passage (same section) states that when drug treatment ends, oppositional processes may persist 'resulting in appearance of withdrawal symptoms, increased vulnerability to relapse, or resistance if treatment is reinstituted'. The 'Pharmacological Strategies' section reinforces this by treating reinstroduction of the same AD as questionable and noting that tolerance may extend to other drugs of the same class. Thus the cited paper does describe this rechallenge failure as a specific form of resistance arising under oppositional tolerance; the only softening is that the paper frames it within a model using 'may', which the paraphrase drops. (LLM, conf=0.85)
- Not checked yetcites [27] matched to “Authors' response to a critique by Jauhar and Hayes of ‘A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guideline evidence-based?’” (2019) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The return of depressive symptoms during maintenance antidepressant treatment was found to occur in a significant proportion of patients in published trials [26, 28].”
What the sources say
- Partly supportedcites [26] matched to “Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience” (2018) sourceExperimental — accuracy not yet measured
The introduction of our copy (pp. 257-267, opening section) does list 'the return of depressive symptoms during long-term maintenance' among the clinical phenomena related to AD, but it is presented as a recognized phenomenon credited to Fava [13] (Fava GA, J Clin Psychiatry 2003), with no trial data attached. No passage in our copy reports that published trials found this return in a significant proportion of patients during maintenance treatment; the only during-treatment figure given is in the 'Paradoxical Effects' section, where Fux et al. [23] observed emergent depressive symptoms in 7 of 80 patients (9%) treated for panic disorder with fluvoxamine — a different population, a different framing (paradoxical/oppositional tolerance rather than maintenance relapse), and not a large proportion. Thus the existence of the phenomenon is supported, while the quantitative/trial-level part of the claim is not. (LLM, conf=0.72)
- Not checked yetcites [28] matched to “A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepressant Therapy (ADAPT-A Study)” (2012) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Resistance may also ensue with loss of clinical effect in a patient who previously responded to antidepressant drug treatment.”
What the sources say
- Supportedcites [26] matched to “Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience” (2018) source
The “Lack or Loss of Efficacy” section says an antidepressant may lose effectiveness after a period of treatment, implying an earlier response. The paper also says continued treatment may lead to loss of efficacy and a treatment-unresponsive course. The claim’s “may” reflects that qualified account. (LLM, conf=0.91)
- Not checked yetcites [28] matched to “A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepressant Therapy (ADAPT-A Study)” (2012) source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Many of the STAR * D findings can be interpreted in light of the oppositional model of tolerance [32]: pharmacological manipulations, either by switching or augmentation (steps 1 and 2) may propel depressive illness into a refractory phase, characterized by low remission, high relapse, and high intolerance (steps 3 and 4).”
What the sources say
- Could not verifycites [32] matched to “Adaptive Treatment Strategies in Chronic Disease” (2008) sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Resistance to re-challenge, loss of clinical effects, paradoxical reactions, withdrawal and postwithdrawal syndromes tend to cluster and may share a common mechanism that has been subsumed under the rubric of oppositional model of tolerance [26, 32].”
What the sources say
- Supportedcites [26] matched to “Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience” (2018) source
The paper’s opening discussion says that withdrawal and other antidepressant-related phenomena may overlap in the same patient, and that these clinical manifestations may be unified under the oppositional model of tolerance. Its Pharmacological Strategies section also links withdrawal phenomena and persistent postwithdrawal disorders to manifestations of oppositional tolerance. (LLM, conf=0.91)
- Could not verifycites [32] matched to “Adaptive Treatment Strategies in Chronic Disease” (2008) sourceExperimental — accuracy not yet measured
The passages from the paper’s section on defining adaptive treatment strategies (page unavailable) discuss changing treatment in response to a patient’s condition, not an oppositional model of tolerance. Searches for that model, withdrawal and postwithdrawal syndromes, resistance to re-challenge, and paradoxical reactions found no passage addressing the claimed clustering or shared mechanism. (LLM, conf=0.75)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
58 more claims · 2 with their cited sources checked
Create a free account to see all 103 claims and to verify the 97 references still open.
- Probably not a substantial claim. 13
- It may state two separate claims as one. 31
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This raises the possibility it may be mistaken for a “treatment-resistant” psychiatric condition.34”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [34]
In the citing paper
“Clinical outcome is the result of several interacting variables: living conditions, patient characteristics, illness features and previous therapeutic experience, self-management (the degree of collaboration of the patient in behavioural and lifestyle terms), and treatment setting (e.g. physician’s attitude and attention, illness behavior).”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Flawed Designs and Unwarranted Assumptions · p. 3
“pharmacological manipulations, either by switching or augmentation (steps 1 and 2)”
§ Flawed Designs and Unwarranted Assumptions · p. 3
“step 1 (open treatment with citalopram)”
Citations
Cites
The Need for a New Medical Model: A Challenge for Biomedicine
Engel, G. L. (1977) · Science · doi:10.1126/science.847460 · Cited by 12,887
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
How to measure comorbiditya critical review of available methods
DEGROOT, V, BECKERMAN, H., LANKHORST, G., & BOUTER, L. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00585-1 · Cited by 1,757
The pre-therapeutic classification of co-morbidity in chronic disease
Feinstein, A. R. (1970) · Journal of Chronic Diseases · doi:10.1016/0021-9681(70)90054-8 · Cited by 1,544
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Streptomycin Treatment of Pulmonary Tuberculosis: A Medical Research Council Investigation
(1948) · BMJ · doi:10.1136/bmj.2.4582.769 · Cited by 986
Depression: A cognitive perspective
LeMoult, J., & Gotlib, I. H. (2019) · Clinical Psychology Review · doi:10.1016/j.cpr.2018.06.008 · Cited by 792
Problems in the “Evidence” of “Evidence-Based Medicine”
Feinstein, A. R., & Horwitz, R. I. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00244-1 · Cited by 653
A "SMART" Design for Building Individualized Treatment Sequences
Lei, H., Nahum-Shani, I., Lynch, K., Oslin, D., & Murphy, S. A. (2012) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032511-143152 · Cited by 557
Feinstein, A. R. (1987) · doi:10.2307/j.ctt1xp3vbc · Cited by 538
Research works printed but not linked: 1
- 3 Salloum NC, Papakostas GI. Staging treatment intensity and defining resistant depression. J Clin Psychiatry. 2019 Jun; 80: 18r12250.
Cited by
Fava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
Self-citationProdromal Symptoms in Depression: A Systematic Review
Benasi, G., Fava, G. A., & Guidi, J. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517953 · Cited by 73
Self-citationHengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320980573 · Cited by 74
Framer, A. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321991274 · Cited by 73
When Anxiety and Depression Coexist: The Role of Differential Diagnosis Using Clinimetric Criteria
Cosci, F., & Fava, G. A. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517518 · Cited by 63
Self-citationUnderstanding Health Attitudes and Behavior
Fava, G. A., Cosci, F., Sonino, N., & Guidi, J. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.10.019 · Cited by 72
Self-citationMunder, T., Geisshüsler, A., Krieger, T., Zimmermann, J., Wolf, M., Berger, T., & Watzke, B. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000521951 · Cited by 43
The emerging role of euthymia in psychotherapy research and practice
Guidi, J., & Fava, G. A. (2020) · Clinical Psychology Review · doi:10.1016/j.cpr.2020.101941 · Cited by 40
Self-citationMarchant, N. L., Barnhofer, T., Coueron, R., Wirth, M., Lutz, A., Arenaza-Urquijo, E. M., Collette, F., Poisnel, G., Demnitz-King, H., Schild, A.-K., et al. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000515669 · Cited by 40
Allostatic Load in Clinical Practice
Fava, G. A., Sonino, N., Lucente, M., & Guidi, J. (2022) · Clinical Psychological Science · doi:10.1177/21677026221121601 · Cited by 49
Self-citationRink, L., Adams, A., Braun, C., Bschor, T., Kuhr, K., & Baethge, C. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000520554 · Cited by 36
The Role of Illness Behavior in the COVID-19 Pandemic
Cosci, F., & Guidi, J. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000513968 · Cited by 34
Self-citationStaging of unipolar depression: systematic review and discussion of clinical implications
Cosci, F., & Fava, G. A. (2022) · Psychological Medicine · doi:10.1017/s0033291722001507 · Cited by 28
“Furthermore, psychotherapy is included among the therapeutic tools, in view of its effectiveness (Fava et al., 2020).”
BackgroundSelf-citationYu, M., Cai, C.-C., Huang, Y., Zhu, Y., Luo, X.-Y., Kong, X., Zhang, W., Li, H.-J., Fang, J.-X., & Zou, Z. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.122527 · Cited by 28
The need for antidepressant withdrawal support services: Recommendations from 708 patients
Read, J., Lewis, S., Horowitz, M., & Moncrieff, J. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115303 · Cited by 24
“…also mentioned that they would like doctors to be better informed about tolerance effects from antidepressants, closely related to withdrawal effects, as well as the myriad side effects and consequences of antidepressant use over the long-term (Fava, 2020; Fava et al. 2020; Read et al., 2017).”
BackgroundConceptual and Clinical Innovations of Well-being Therapy
Guidi, J., & Fava, G. A. (2021) · International Journal of Cognitive Therapy · doi:10.1007/s41811-021-00101-1 · Cited by 30
Self-citationLucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 24
“…may stem from an assortment of less common pathophysiologic is unknown whether the biological features of SRI resistance differ between the aforementioned response profiles or whether there are contributory iatrogenic effects resulting from long-term or repeated courses of ADM treatment [21–23].”
Schnyder, U. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000527462 · Cited by 19
Cosci, F., Romanazzo, S., Mansueto, G., Rontani, P., Levitan, M. N., Halkjœr-Lassen, R. D., Quagliato, L. A., Nakamura, T., Uematsu, K., Nardi, A. E., et al. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001491 · Cited by 16
Self-citationDifficult-To-Treat Depression. Scoping Review.
Paganin, W., Signorini, S. G., & Sciarretta, A. (2023) · PubMed Central · doi:10.36131/cnfioritieditore20230302 · Cited by 28
“…Review Article International Journal of Neuropsychopharmacology UK 8 Fava & Rafanelli, 2019 Editorial Psychotherapy and Psychosomatics Switzerland 9 Fava et al., 2020 Editorial Psychotherapy and Psychosomatics Switzerland 10 McAllister-Williams et al., 2020 Review Article Journal of Affective…”
BackgroundInfluentialThe experience of ‘treatment‐resistant’ depression: A qualitative meta‐synthesis
Crowe, M., Manuel, J., Carlyle, D., Thwaites, B., & Lacey, C. J. (2023) · International Journal of Mental Health Nursing · doi:10.1111/inm.13107 · Cited by 16
Guidi, J., & Fava, G. A. (2025) · Clinical Psychology Review · doi:10.1016/j.cpr.2025.102616 · Cited by 15
Self-citationClinical Use of Staging in Psychiatry
Fava, G. A. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000538526 · Cited by 12
“The two clinical situations belong to different stages [6] and imply different levels of responsiveness, which is likely to play a particularly important role when comorbidities occur [41, 42].”
BackgroundInfluentialSelf-citationExploring cariprazine as a treatment option for varied depression symptom clusters
Pejušković, B., Munjiza, A., & Pešić, D. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1442699 · Cited by 11
Rethinking treatment-resistant depression to quasi-tenacious depression
Arjmand, S., Grassi‐Oliveira, R., & Wegener, G. (2023) · European Psychiatry · doi:10.1192/j.eurpsy.2022.2353 · Cited by 8
“), accompanied possible comorbidities (both somatic and psychiatric), patient’s school of thoughts, the currently used rating scales, or finally the disease classification system that might intrinsically lead to a misconstrued diagnosis [7, 10].”
BackgroundrTMS and treatment-resistant depression: The need to consider class action!
Malhi, G. S., Bell, E., Mannie, Z. N., Boyce, P. M., Hopwood, M., Bassett, D. L., Mulder, R., Porter, R., & Lyndon, B. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211025094 · Cited by 6
“Australian & New Zealand Journal of Psychiatry, 56(4) intervention (Fava et al., 2020; Malhi et al., 2021a), and importantly, the threshold for categorising treatment non-response will inevitably vary from individual to individual, and clinician to clinician, creating the likelihood of misapplication and the possibili…”
BackgroundNeuromodulations in Psychiatric Disorders: Emerging Lines of Definition
Liu, X., & Wang, H. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000542163 · Cited by 6
“In the longitudinal course, it is also necessary to consider the iatrogenic and psychosocial factors, response to treatment, residual symptomatology, and behavioral toxicity within a comprehensive staging framework [66 – 68].”
Brexpiprazole versus placebo or other antidepressive agents for treating depression
Ralovska, S., Koychev, I. G., Marinov, P., Furukawa, T. A., Mulsant, B. H., & Cipriani, A. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013866.pub2 · Cited by 4
Miao, X., Yin, I. Z., Zhang, H., & Siu, K. W. M. (2025) · Applied Research in Quality of Life · doi:10.1007/s11482-025-10490-6 · Cited by 8
Kim, J., Stewart, R. J., Kang, H., Kim, J., Lee, J., Ms, J., Lee, J.-Y., Kim, S., & Shin, I. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.06.015 · Cited by 5
A case of treatment-resistant depression in an older adult and a discussion of treatment options
Pope, E., Muthukrishnan, S., Phillips, J., & Phillips, S. M. (2021) · BJPsych Bulletin · doi:10.1192/bjb.2021.105 · Cited by 3
Gender differences in obstructive sleep apnea with comorbid treatment-resistant depression
Kasurak, E., Hawken, E. R., Kolar, D., & Jokic, R. (2023) · Sleep Science and Practice · doi:10.1186/s41606-023-00087-z · Cited by 3
“Existing literature identi es possible explanations for this phenomenon: [1] women may perceive snoring as “un lady-like” and avoid seeking care (31), and [2] a large proportion of women with OSA do not report any of the “classic” symptoms such as snoring or apneas and endorse insomnia, headaches, and tiredness (32).”
BackgroundLi, L., Chen, J., Zhang, X., Zhang, X., Fu, Y., Jiang, H., Yin, T., Zhang, Y., Li, X., Hu, M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18091395 · Cited by 3
“However, current clinical antidepressants targeting known etiological factors, like tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs), are restricted through delayed onset, efficacy, and significant side effects [4].”
Brexpiprazole versus placebo or other antidepressive agents for treating depression
Ralovska, S., Koychev, I. G., Crescenzo, F. D., Marinov, P., & Cipriani, A. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013866 · Cited by 2
Prediction of treatment-resistant depression using the 23andMe survey data
Vairavan, S., Tian, C., Hinds, D. A., Narayan, V. A., & Li, Q. S. (2025) · Scientific Reports · doi:10.1038/s41598-025-08460-x · Cited by 1
Esketamine for treatment-resistant depression in adults
Gastaldon, C., Laurenzi, P. F., Schoretsanitis, G., Papola, D., Cristea, I. A., Naudet, F., Ostuzzi, G., & Barbui, C. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015071 · Cited by 2
Fava, G. A. (2020) · Ärztliche Psychotherapie · doi:10.21706/aep-15-4-275
Self-citationMünder, T., Geisshüsler, A., Krieger, T., Zimmermann, J., Wolf, M., Berger, T., & Watzke, B. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/5s6ap
Leggett, K., Hennessy, L. A., McAndrew, M., Price, G. W., & Rodger, J. (2022) · Research Square · doi:10.21203/rs.3.rs-1675887/v1
Introduction to Deprescribing Psychiatric Medications
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg001
Safe Deprescribing of Antidepressants
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg002
Well-Being Therapy for Depression
Romanazzo, S., & Cosci, F. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4402-2_14
Self-citationLes manifestations cliniques associées à la toxicité comportementale
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00003-0
Self-citationFava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00007-8
Self-citationStratégies et options pharmacologiques
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00008-x
Self-citationPrévention de la dépendance et de la symptomatologie du sevrage dus aux traitements antidépresseurs
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00012-1
Self-citationKidyaeva, A. V., & Nasyrova, R. F. (2025) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2025-3-1196
Chapter 4. The Myth of Treatment Resistance?
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551937.lg04
Metadata
- Authors
- Fava, G. A., Cosci, F., Guidi, J., & Rafanelli, C.
- Affiliations
- University at Buffalo, State University of New York (US)
- University of Florence (IT)
- University of Bologna (IT)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2020
- Volume
- 89
- Issue
- 5
- Pages
- 265-273
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W3017554838
- Cited by
- 48
- References
- 75
- Citations by year
- 2025: 6 · 2024: 12 · 2023: 6 · 2022: 7 · 2021: 13 · 2020: 4
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- treatment resistance, depression, antidepressant treatment, iatrogenic disease, misdiagnosis, diagnostic heterogeneity, biological heterogeneity, psychiatric comorbidity, treatment response assessment
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Drug Resistance, Humans, Deception, Randomized Controlled Trials as Topic, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.